ATE525908T1 - Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen - Google Patents

Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen

Info

Publication number
ATE525908T1
ATE525908T1 AT03808435T AT03808435T ATE525908T1 AT E525908 T1 ATE525908 T1 AT E525908T1 AT 03808435 T AT03808435 T AT 03808435T AT 03808435 T AT03808435 T AT 03808435T AT E525908 T1 ATE525908 T1 AT E525908T1
Authority
AT
Austria
Prior art keywords
antigen
cells
cd1a
surface markers
loaded
Prior art date
Application number
AT03808435T
Other languages
English (en)
Inventor
Jacques Banchereau
Anna K Palucka
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Application granted granted Critical
Publication of ATE525908T1 publication Critical patent/ATE525908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03808435T 2002-12-04 2003-12-04 Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen ATE525908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43079102P 2002-12-04 2002-12-04
PCT/US2003/038553 WO2004050855A2 (en) 2002-12-04 2003-12-04 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Publications (1)

Publication Number Publication Date
ATE525908T1 true ATE525908T1 (de) 2011-10-15

Family

ID=32469531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03808435T ATE525908T1 (de) 2002-12-04 2003-12-04 Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen

Country Status (7)

Country Link
US (1) US20060239962A1 (de)
EP (2) EP1567014B1 (de)
JP (3) JP4662776B2 (de)
CN (1) CN100337686C (de)
AT (1) ATE525908T1 (de)
AU (1) AU2003302504B2 (de)
WO (1) WO2004050855A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582426A1 (en) * 2004-10-04 2006-04-13 Biovaxim Limited Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
US7919265B2 (en) * 2006-06-21 2011-04-05 Children's Research Institute Antibody-based method for isolating Th1 and Th2 helper lymphocytes from human peripheral blood
US20090011458A1 (en) * 2007-06-19 2009-01-08 Johnson Paul E Method for selectively staining microorganisms
CL2007002825A1 (es) 2007-09-28 2008-05-30 Univ De Chile Oncobiomed Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
RU2012127811A (ru) * 2009-12-04 2014-01-10 Стем Селл Энд Ридженерэйтив Медсин Интернэшнл, Инк. Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток
US20130129713A1 (en) 2010-08-04 2013-05-23 Ieo - Istituto Europeo Di Oncologia S.R.L. Method of antigen loading for immunotherapy
WO2013167156A1 (en) * 2012-05-11 2013-11-14 Otto-Von-Guericke-Universität Magdeburg Transplantation of modified monocytes
CN102813916B (zh) * 2012-09-05 2015-03-11 北京希普生国际生物医学研究院 一种快速获取树突状细胞疫苗的制备方法及其应用
CN105802908B (zh) * 2014-12-29 2020-06-23 复旦大学附属肿瘤医院 一种体外制备肿瘤抗原特异性cd8+干细胞样记忆性t淋巴细胞的方法
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3167898A1 (de) 2015-11-11 2017-05-17 IEO - Istituto Europeo di Oncologia Srl Verfahren zur gewinnung von tumorpeptiden und verwendungen davon
CN107541498A (zh) * 2016-06-27 2018-01-05 复旦大学附属肿瘤医院 一种tcr基因修饰的cd8+t记忆性干细胞的制备方法及其用途
JP7146732B2 (ja) * 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
JP6782503B1 (ja) * 2019-12-12 2020-11-11 康基 土方 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法
CN112010960A (zh) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 一种肿瘤抗原复合物体外致敏dc、t细胞获得肿瘤特异性杀伤细胞ctl及其制备方法
MX2023005201A (es) 2020-11-04 2023-06-28 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
CN112458058B (zh) * 2020-11-24 2023-09-01 康九生物科技(长春)有限公司 一种过表达traf6的dc细胞、dc细胞疫苗及构建方法和应用
BR112023018832A2 (pt) 2021-03-17 2023-12-26 Myeloid Therapeutics Inc Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas
EP4337268A4 (de) 2021-05-11 2025-06-04 Myeloid Therapeutics, Inc. Verfahren und zusammensetzungen zur genomischen integration
CN114686431B (zh) * 2022-03-30 2023-09-15 益诺思生物技术南通有限公司 一种免疫毒性的评价方法及模型
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用
CN115463220A (zh) * 2022-07-27 2022-12-13 江苏医药职业学院 朗格汉斯细胞源外泌体作为经皮免疫抗原递呈载体的应用
CN116286637A (zh) * 2023-03-28 2023-06-23 中山大学附属第七医院(深圳) 一种靶向肽功能化的树突状细胞外泌体及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
WO1999003972A1 (en) * 1997-07-15 1999-01-28 Takara Shuzo Co., Ltd. Cytotoxic t lymphocytes
ES2286530T3 (es) * 1997-10-10 2007-12-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos antagonistas del antigeno carcinoembrionario (cea).
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
WO2001021653A2 (en) * 1999-09-23 2001-03-29 Corixa Corporation Ovarian tumor antigen and methods of use therefor
EP1299523B1 (de) * 2000-07-10 2008-12-24 Eppendorf Ag Verfahren zur modifizierung von biologischen zellen
WO2002072013A2 (en) 2001-03-09 2002-09-19 Baylor Research Institute Method of treating malignancies through induction of blood immune responses

Also Published As

Publication number Publication date
EP1567014A2 (de) 2005-08-31
EP2301356A2 (de) 2011-03-30
EP2301356A3 (de) 2012-05-30
EP1567014B1 (de) 2011-09-28
JP2011046717A (ja) 2011-03-10
JP5498333B2 (ja) 2014-05-21
JP2006508664A (ja) 2006-03-16
EP1567014A4 (de) 2006-02-01
CN100337686C (zh) 2007-09-19
AU2003302504B2 (en) 2007-03-08
WO2004050855A2 (en) 2004-06-17
AU2003302504A1 (en) 2004-06-23
WO2004050855A3 (en) 2005-02-03
JP5919226B2 (ja) 2016-05-18
CN1744822A (zh) 2006-03-08
US20060239962A1 (en) 2006-10-26
JP4662776B2 (ja) 2011-03-30
JP2013224313A (ja) 2013-10-31

Similar Documents

Publication Publication Date Title
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
Fu et al. Allogeneic stem cells from deciduous teeth in treatment for periodontitis in miniature swine
ATE420946T1 (de) Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine
CN102911918A (zh) 一种基因工程细胞及其在nk细胞扩增中的应用
KR101327297B1 (ko) 유기무기 복합체 분산액 및 그것을 사용하여 제조되는 세포 배양 기재, 및 그들의 제조 방법
NZ771198A (en) Engineered immunostimulatory bacterial strains and uses thereof
JP2013512694A5 (de)
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
WO2004053072A3 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
MX2008007286A (es) Ingenieria in vivo de superficie celular.
NO981374D0 (no) Dendrittcellestimulerende faktor
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
WO2001054716A3 (en) Genetically engineered tumor cell vaccines
ZA200301466B (en) Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells.
CA2354046A1 (en) New cancer treatments
CN100553926C (zh) 采用热压印制作生物表皮形貌复制模板的复制方法
SI1664319T1 (sl) Postopek za pripravo kapsularnega polisaharida zauporabo v konjugatnih vakcinah
DE19602985A1 (de) Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
SI1530628T1 (sl) Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
Kedar et al. In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes
Weiner DNA vaccines: Crossing a line in the sand introduction to special issue
IL276374B1 (en) Natural killer cells are resistant to transforming growth factor beta
EP2147682A3 (de) Impfstoff mit immunisolierten Zellen zur Herstellung eines Immunmodulators
Liu et al. Periodic arrangement of lipopolysaccharides nanostructures accelerates and enhances the maturation processes of dendritic cells
Maia et al. In vitro evaluation of acellular dermal matrix as a three‐dimensional scaffold for gingival fibroblasts seeding

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties